Early clinical experience with subcutaneous GR43175 in acute migraine: An overview

Cephalalgia ◽  
1989 ◽  
Vol 9 (9_suppl) ◽  
pp. 73-77
Author(s):  
P Tfelt-Hansen ◽  
J Brand ◽  
P Dano ◽  
A Doenicke ◽  
LJ Findley ◽  
...  
Keyword(s):  
Side Effects ◽  
Clinical Experience ◽  
Receptor Agonist ◽  
Response Rates ◽  
Acute Migraine ◽  
Double Blind ◽  
Subcutaneous Injections ◽  
Early Clinical Experience ◽  
Dose Ranging ◽  
Blind Trials

In six European clinics 111 migraine patients were treated in a series of open dose-ranging studies with subcutaneous injections of 1 to 4 mg GR43175, a novel 5-HT1-like receptor agonist. Response rates after 20–30 min were dose related and rose from 33% with 1 mg to 96% with 4 mg GR43175. Side effects were minor and transient. These promising results warrant confirmation in placebo-controlled double-blind trials.

Tolfenamic Acid, Metoclopramide, Caffeine and Their Combinations in The Treatment of Migraine Attacks

Cephalalgia ◽  
1984 ◽  
Vol 4 (4) ◽  
pp. 253-263 ◽  
Author(s):  
Riitta A Tokola ◽  
Pentti Kangasniemi ◽  
Pertti J Neuvonen ◽  
Olavi Tokola
Keyword(s):  
Side Effects ◽  
Clinical Studies ◽  
Tolfenamic Acid ◽  
Acute Migraine ◽  
Double Blind ◽  
Better Than

Tolfenamic acid is a fenamate which inhibits prostaglandin (PG) biosynthesis and may act as a PG antagonist as well. Caffeine and metoclopramide are used in combination with analgesics and ergotamine in the treatment of migraine attacks, but controlled clinical studies on fixed combinations with analgesics are rare. The effects of orally given tolfenamic acid (200 mg), caffeine (100 mg), metoclopramide (10 mg), tolfenamic acid + caffeine (200 mg + 100 mg), tolfenamic acid + metoclopramide (200 mg + 10 mg) and placebo were studied in 49 migraine patients (3 men, 46 women) in a double-blind randomized cross-over study comprising 482 migraine attacks. The patients were allowed to take either one or two capsules of each preparation for an attack. Additional drugs were allowed after 3 h. Parameters characterizing the effects and side-effects of the drugs were registered. Tolfenamic acid and its combinations were found to be effective in the treatment of acute migraine, but caffeine and metoclopramide alone did not differ from placebo. Combination with metoclopramide was better than tolfenamic acid alone as judged by the smaller dose needed and the intensity of attack. Between tolfenamic acid alone and its caffeine combination there were no statistically significant differences.

Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study

1998 ◽  
Vol 5 (5) ◽  
pp. 469-477 ◽  
Author(s):  
Carl Dahlof ◽  
Leon Hogenhuis ◽  
Jes Olesen ◽  
Henri Petit ◽  
Jacques Ribbat ◽  
...  
Keyword(s):  
Clinical Experience ◽  
Acute Treatment ◽  
Early Clinical Experience ◽  
Dose Ranging

A Double-Blind Study of Ibuprofen Versus Placebo in the Treatment of Acute Migraine Attacks

Cephalalgia ◽  
1992 ◽  
Vol 12 (3) ◽  
pp. 169-171 ◽  
Author(s):  
Reidar Kloster ◽  
Knut Nestvold ◽  
Steinar T Vilming
Keyword(s):  
Side Effects ◽  
Initial Dose ◽  
Acute Treatment ◽  
Blind Study ◽  
Double Blind Study ◽  
Acute Migraine ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Inflammatory Drug ◽  
Anti Inflammatory

The efficacy of ibuprofen, a non-steroidal anti-inflammatory drug, was assessed in the acute treatment of migraine. Twenty-five patients completed a double-blind placebo-controlled multicrossover trial. The initial dose of ibuprofen was 1200 mg. Six migraine attacks were randomly treated in each patient, three with ibuprofen and three with placebo. The results indicated a statistically significant reduction in the duration of the migraine attacks and also a statistically significant reduction in the severity of headache and nausea in the ibuprofen-treated attacks. The use of additional medication was significantly reduced in the ibuprofen-treated attacks (25.6% vs 57.5%), No serious side effects were reported. Ibuprofen is valuable in the treatment of acute migraine attacks.

Evaluation of a Novel Solubilized Formulation of Ibuprofen in the Treatment of Migraine Headache: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study

Cephalalgia ◽  
2000 ◽  
Vol 20 (4) ◽  
pp. 233-243 ◽  
Author(s):  
DE Kellstein ◽  
RB Lipton ◽  
R Geetha ◽  
K Koronkiewicz ◽  
FT Evans ◽  
...  
Keyword(s):  
Migraine Headache ◽  
Response Rates ◽  
Global Evaluation ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Dose Ranging

A total of 729 migraine sufferers with moderate to severe baseline pain evaluated a single 200, 400 or 600 mg dose of a new liquigel formulation of ibuprofen over 8 h. Ibuprofen liquigels were significantly superior to placebo for cumulative headache response (pain reduced to mild or none) from 0.5 (600 mg) or 1 h (200 and 400 mg) to 8 h. At 2 h, respective headache response rates for ibuprofen 200, 400 and 600 mg and placebo were 64%, 72%, 72% and 50%. All three doses were also significantly superior to placebo for 2-h pain-free (25%, 28%, 29% and 13%, respectively) and for proportions with mild or no limitation of activity (2-8 h). Ibuprofen liquigels were generally superior to placebo for reducing photophobia, phonophobia, or nausea (1-4 h) and for global evaluation. All doses were well tolerated. These data demonstrate that ibuprofen liquigels relieve the pain, ancillary symptoms, and limitation of activity, of migraine.

Flunarizine in the Prevention of Classical Migraine: A Placebo-Controlled Evaluation

Cephalalgia ◽  
1985 ◽  
Vol 5 (2_suppl) ◽  
pp. 135-140 ◽  
Author(s):  
G Mentenopoulos ◽  
Th Manafi ◽  
J Logothetis ◽  
S Bostantzopoulou
Keyword(s):  
Side Effects ◽  
Clinical Experience ◽  
Calcium Entry ◽  
Drug Group ◽  
Calcium Entry Blocker ◽  
Early Clinical Experience ◽  
Pharmacological Data ◽  
Free Running ◽  
Controlled Evaluation ◽  
Drug Free

Pharmacological data and early clinical experience have suggested that the calcium entry blocker flunarizine may be a valuable asset in the prophylaxis of migraine. This was supported by a study in twenty patients with classical migraine who were, after a drug-free running-in phase, orally treated with either placebo or flunarizine (10 mg at night) for three to four months. Flunarizine significantly reduced the frequency, duration and severity of the migraine attacks. A corrected migraine index, based on these three variables, was reduced by 82% in the drug group but increased by 66% in the control patients. Only one patient did not clearly benefit from flunarizine, and the response in another illustrated that flunarizine has to be given for at least four months before its efficacy can be judged in some cases. No side effects occurred.

Efficacy, Safety and Tolerability of Oral Eletriptan in the Acute Treatment of Migraine: Results of A Phase Iii, Multicentre, Placebo-Controlled Study Across Three Attacks

Cephalalgia ◽  
2002 ◽  
Vol 22 (1) ◽  
pp. 23-32 ◽  
Author(s):  
R Stark ◽  
C Dahlöf ◽  
S Haughie ◽  
J Hettiarachchi ◽  
Keyword(s):  
Acute Treatment ◽  
Receptor Agonist ◽  
Phase Iii ◽  
Controlled Study ◽  
Acute Migraine ◽  
Initial Attack ◽  
Double Blind ◽  
Lower Recurrence Rate ◽  
Parallel Group ◽  
Headache Relief

The efficacy, safety and tolerability of the 5-HT1B/1D receptor agonist eletriptan (40 mg and 80 mg) in acute treatment of migraine was evaluated in a multinational, randomized, double-blind, parallel-group, placebo-controlled, three-attack study treating 1153 patients. In the initial attack, significantly more eletriptan patients reported headache relief and complete pain relief at 2 h vs. placebo (40 mg 62% and 32%, 80 mg 65% and 34%, placebo 19% and 3%; P < 0.0001). Headache relief occurred faster after eletriptan, with more patients at both doses reporting relief 30 min ( P < 0.01) and 1 h ( P < 0.0001) after treatment than after placebo. There was a significantly lower recurrence rate with eletriptan 80 mg compared with placebo ( P < 0.01). Adverse events for all treatments were generally mild or moderate and self-limiting. Eletriptan 40 mg and eletriptan 80 mg both appear to be effective and well-tolerated acute migraine treatments.

Sign in / Sign up

Export Citation Format

Share Document